Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice

M. S. Bartlett, T. D. Edlind, C. H. Lee, R. Dean, S. F. Queener, M. M. Shaw, J. W. Smith

Research output: Contribution to journalArticle

20 Scopus citations


Albendazole, a benzimidazole derivative widely used for treating helminth infections, was successfully used to treat and prevent development of Pneumocystis carinii pneumonia in transtracheally inoculated immunosuppressed mice. For treatment, 3 weeks postinoculation, albendazole at 300 and 600 mg/kg of body weight per day was administered in food for 3 weeks. For prophylaxis, albendazole was begun on the same day as inoculation at 300 mg/kg/day for 7 days, and then the dose was reduced to 150 mg/kg/day for 35 additional days. With these regimens, albendazole was effective both for treatment and prophylaxis. Both dexamethasone-immunosuppressed and L3T4+ monoclonal antibody-immunosuppressed mouse models were used, and albendazole inhibited P. carinii infection in both.

Original languageEnglish (US)
Pages (from-to)1834-1837
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Issue number8
StatePublished - 1994

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice'. Together they form a unique fingerprint.

  • Cite this